💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Myriad Genetics, Inc. (MYGN)
« Back to company indexMYGN Chatter Timeline
Stock Ticker for MYGN
Most Active Tweeters for MYGN
| User | Tweets |
|---|---|
| @stock_titan | 7 |
| @Tickeron | 6 |
| @FlashAlert_me | 6 |
| @sbwcws | 5 |
| @MarcJacksonLA | 5 |
Recent Tweets for MYGN
 |
@Gambiste1 RT @CSIMarket: $MYGN #StockMarket #MyriadGenetics issued first quarter of 2021 Results on https://t.co/savSNTKlN1: From the preceding quart… May 7th 2021, 6:05am |
 |
@CSIMarket $MYGN #StockMarket #MyriadGenetics issued first quarter of 2021 Results on https://t.co/savSNTKlN1: From the preced… https://t.co/GkjloN5gw8 May 7th 2021, 5:05am |
 |
@MarcJacksonLA $MYGN BTIG Maintains Buy Rating On Myriad Genetics, $37 PT https://t.co/CJlfiMbk9s May 6th 2021, 2:05pm |
 |
@shortablestocks $MYGN is short sale restricted for 2021-05-06. https://t.co/1184JCs8Xf May 6th 2021, 1:05pm |
 |
@insiderbuyings $MYGN new insider selling: 19360 shares. https://t.co/qVAU9HFooF May 6th 2021, 7:05am |
 |
@Tickeron $MYGN's 10-day Moving Average moved above its 50-day Moving Average on May 3, 2021. View odds for this and other in… https://t.co/zGek8OPyYq May 6th 2021, 5:05am |
 |
@InsiderAlerts4U $MYGN: New Insider Filing on MYRIAD GENETICS INC's Chief Scientific Officer JERRY S LANCHBURY: https://t.co/FCv3zAyAMm May 6th 2021, 3:05am |
 |
@EZMoney_41 $MYGN Still going down https://t.co/FAZMjDLEiB May 6th 2021, 2:05am |
 |
@StockTexts $MYGN Myriad Genetics, Inc. SEC Filing: Form 4 https://t.co/LNbMOpZt0x May 6th 2021, 12:05am |
 |
@fintel_io Insider Jerry S Lanchbury reports selling 19,360 shares of $MYGN for a total cost of $618,948.88 https://t.co/kWMYSy7Cdq May 5th 2021, 11:05pm |
 |
@FlashAlert_me $MYGN [15s. delayed] filed SEC form 4: Chief Scientific Officer LANCHBURY JERRY S: Disposed 19,360 of Common Stock… https://t.co/xa1gs4MA8m May 5th 2021, 11:05pm |
 |
@kevinjaybe $MYGN Myriad Genetics Ceo Paul J. Diaz To Present At Bank Of America Securities 2021 Virtual Health Care Conference https://t.co/zuLR1eeAQo May 5th 2021, 8:05pm |
 |
@stock_titan $MYGN Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference https://t.co/8ANPX4WlJ1 May 5th 2021, 8:05pm |
 |
@TerraPharma1 $MYGN down 5% after earnings. "Transformation" plan not too convincing?? May 5th 2021, 2:05pm |
|
@StockTexts $MYGN Myriad Genetics, Inc. SEC Filing: Form 10-Q https://t.co/NSG0qGc4X2 May 5th 2021, 11:05am |
 |
@Allstocknews $MYGN New Form 10-Q for Myriad Genetics, Inc. From our Stock News Alerts App May 5th 2021, 11:05am |
|
@fintel_io $MYGN / Myriad Genetics files form 10-Q https://t.co/10uBQNeH4w May 5th 2021, 11:05am |
 |
@EdgarInsider A Form 10-Q [Quarterly Report] filing has been made with the SEC: $MYGN MYRIAD GENETICS INC https://t.co/M8z5SWkifT May 5th 2021, 11:05am |
|
@FlashAlert_me $MYGN [15s. delayed] filed form 10-Q on May 05, 07:05:47 https://t.co/XJoT78JMMf May 5th 2021, 11:05am |
|
@Tickeron $MYGN's 10-day Moving Average crossed above its 50-day Moving Average on May 3, 2021. View odds for this and other… https://t.co/oHYiAD0duG May 4th 2021, 11:05pm |
 |
@42Stocks https://t.co/dtAK7h3mik 2021-MAY-04 7:15pm $MYGN #MyriadGenetics up 4.01% = $92.9 million gain. (May 04) Myriad G… https://t.co/cXvWNpGlaa May 4th 2021, 11:05pm |
 |
@CapitolistPig Just a reminder that $MYGN has still not disclosed all the endpoints from their failed trial https://t.co/qMR6k1ciQH May 4th 2021, 3:05pm |
 |
@stockmktgenius $MYGN Myriad Genetics, Inc. - C Top stock up 196% from low. Close: 30.40 VolvsAvg: 1.27 Liq: $19M https://t.co/3PaXRdedRG May 4th 2021, 6:05am |
 |
@newsfilterio Myriad Genetics EPS beats by $0.09, beats on revenue $MYGN https://t.co/BoQDeTUiC6 May 4th 2021, 12:05am |
 |
@Briefingcom $MYGN: Myriad Genetics beats by $0.09, beats on revs https://t.co/cyrte7gfnc May 3rd 2021, 10:05pm |
 |
@Estimize $MYGN beats the Estimize EPS Consensus by 6c and the Estimize Revenue Consensus by $15.73M. Reports FQ3 earnings of… https://t.co/ZbPhmetasx May 3rd 2021, 8:05pm |
|
@Estimize $MYGN reports FQ3 earnings of -6c EPS and $173.10M Revs - https://t.co/s2vQUaEhnP May 3rd 2021, 8:05pm |
 |
@GeneticsShare $MYGN Myriad Genetics Delivers 12% Sequential Revenue Growth In March 2021 Quarter - CML News https://t.co/mY6JJwy5Fn May 3rd 2021, 8:05pm |
|
@MarcJacksonLA $MYGN Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic T… https://t.co/kl52x75cd4 May 3rd 2021, 8:05pm |
 |
@sbwcws Myriad Genetics reports Q3 EPS 6c, consensus (14c) $MYGN May 3rd 2021, 8:05pm |
|
@EdgarInsider New Form 8-K [Press/News Current Report] entry filed by $MYGN MYRIAD GENETICS INC https://t.co/SLCdj6WM3t May 3rd 2021, 8:05pm |
|
@Allstocknews $MYGN Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strat From our Stock News Alerts App May 3rd 2021, 8:05pm |
|
@kevinjaybe $MYGN Myriad Genetics Delivers 12% Sequential Revenue Growth In March 2021 Quarter, Company Executes On Strategic T… https://t.co/H3Mw7lkUxj May 3rd 2021, 8:05pm |
|
@MarcJacksonLA $MYGN $LH Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp https://t.co/LX47EeiVkk May 3rd 2021, 8:05pm |
|
@FlashAlert_me $MYGN [15s. delayed] filed form 8-K on May 03, 16:05:28 https://t.co/uBqe50vQcj May 3rd 2021, 8:05pm |
|
@fintel_io $MYGN / Myriad Genetics files form 8-K - Results of Operations and Financial Condition - 8-K https://t.co/10uBQNeH4w May 3rd 2021, 8:05pm |
|
@MarcJacksonLA $MYGN Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial O… https://t.co/1qVouDDzwk May 3rd 2021, 8:05pm |
|
@stock_titan $MYGN Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic T… https://t.co/GQpfcXbOU1 May 3rd 2021, 8:05pm |
|
@MarcJacksonLA $MYGN Myriad Genetics Targets To Be Profitable By Q4 - Quick Facts | NASDAQ https://t.co/7MLgTwaeQB May 3rd 2021, 8:05pm |
 |
@NewsQuantified $MYGN announced that it has entered into a definitive agreement to sell select operating assets and intellectual pr… https://t.co/jrZ9pbcCDX May 3rd 2021, 6:05pm |
|
@Gambiste1 RT @EarningsPoll: $MYGN earnings 5/3 after hours. How will the stock react? May 3rd 2021, 5:05pm |
 |
@EarningsPoll $MYGN earnings 5/3 after hours. How will the stock react? May 3rd 2021, 4:05pm |
 |
@SmallCapsDaily $MYGN Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmunes Vectra Testing Business to Labcorp Glob… https://t.co/lhFueEKhNE May 3rd 2021, 4:05pm |
|
@Estimize $MYGN reports after the close, Estimize Consensus +0.03 EPS and +2.95M Revs compared to WS - https://t.co/zJe2fw53Z6 May 3rd 2021, 3:05pm |
|
@sbwcws LabCorp's Vectra deal likely not the last for this year, says William Blair $LH $MYGN May 3rd 2021, 2:05pm |
|
@Briefingcom $MYGN: Myriad Genetics began to implement the second phase of its transformation plan this quarter, expects to be... https://t.co/l3fFr3ToEz May 3rd 2021, 1:05pm |
 |
@otcdynamics $MYGN Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial O… https://t.co/BPpba2Dhey May 3rd 2021, 11:05am |
|
@sbwcws Myriad Genetics expects to be profitable by 4Q21 $MYGN May 3rd 2021, 11:05am |
|
@stock_titan $MYGN Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp https://t.co/l2uh1kmHcc May 3rd 2021, 11:05am |
|
@FlashAlert_me $MYGN [15s. delayed]: Issued Press Release on May 03, 07:00:00: Myriad Genetics to Update Progress on Transformatio… https://t.co/k2nYxJXESH May 3rd 2021, 11:05am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
